Literature DB >> 25562579

Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.

J MacLaren Kelly1, Ewgeni Jakubovski, Michael H Bloch.   

Abstract

OBJECTIVE: Most patients with anxiety disorders receive treatment in primary care settings. Limited moderator data are available to inform clinicians of likely prognostic outcomes for individual patients. We identify baseline characteristics associated with outcome in adults seeking treatment for anxiety disorders.
METHOD: We conducted an exploratory moderator analysis from the Coordinated Anxiety Learning and Management (CALM) trial. In the CALM trial, 1,004 adults who met DSM-IV criteria for generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and/or posttraumatic stress disorder (PTSD) were randomized to usual care (UC) or a collaborative care intervention (ITV) of cognitive-behavioral therapy and/or pharmacotherapy between June 2006 and April 2008. Logistic regression was used to examine baseline characteristics associated with remission and response overall and by treatment condition. Receiver operating curve (ROC) analyses identified subgroups associated with similar likelihood of response and remission of global anxiety symptoms. Remission was defined as score < 6 on the 12-item Brief Symptom Inventory (BSI-12) anxiety and somatization subscales. Response was defined as at least 50% reduction on BSI-12, or meeting remission criteria.
RESULTS: Randomization to ITV over UC was often the strongest predictor of outcome. Several baseline patient characteristics were associated with poor treatment outcome including comorbid depression, increased severity of underlying anxiety disorder(s) (P < .001), low socioeconomic status (perceived [P < .001] and actual [P < .05]), and limited social support (P < .001). Patient characteristics associated with particular benefit from ITV were being female (P < .05), increased depression (P < .01)/GAD severity (P < .05), and low socioeconomic status (P < .05). ROC analysis demonstrated prognostic subgroups with large differences in response likelihood.
CONCLUSIONS: Further research should focus on the effectiveness of implementing the ITV intervention of CALM in community treatment centers where patients typically are of low socioeconomic status and may particularly benefit from ITV. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00347269. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25562579      PMCID: PMC4930076          DOI: 10.4088/JCP.13m08922

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  50 in total

1.  A meta-analysis of the influence of comorbidity on treatment outcome in the anxiety disorders.

Authors:  Bunmi O Olatunji; Josh M Cisler; David F Tolin
Journal:  Clin Psychol Rev       Date:  2010-05-09

2.  Prediction of outcome in the behavioural treatment of panic disorder with agoraphobia.

Authors:  Jonas Ramnerö; Lars-Göran Ost
Journal:  Cogn Behav Ther       Date:  2004

3.  Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment.

Authors:  T A Brown; D H Barlow
Journal:  J Consult Clin Psychol       Date:  1995-10

4.  Outcome of anxiety and depressive disorders in primary care.

Authors:  C Ronalds; F Creed; K Stone; S Webb; B Tomenson
Journal:  Br J Psychiatry       Date:  1997-11       Impact factor: 9.319

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002.

Authors:  Sanjat Kanjilal; Edward W Gregg; Yiling J Cheng; Ping Zhang; David E Nelson; George Mensah; Gloria L A Beckles
Journal:  Arch Intern Med       Date:  2006-11-27

7.  Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy.

Authors:  Cindy J Aaronson; M Katherine Shear; Raymond R Goetz; Laura B Allen; David H Barlow; Kamila S White; Susan Ray; Roy Money; John R Saksa; Scott W Woods; Jack M Gorman
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

8.  Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS).

Authors:  Laura Campbell-Sills; Sonya B Norman; Michelle G Craske; Greer Sullivan; Ariel J Lang; Denise A Chavira; Alexander Bystritsky; Cathy Sherbourne; Peter Roy-Byrne; Murray B Stein
Journal:  J Affect Disord       Date:  2008-05-16       Impact factor: 4.839

Review 9.  The impact of personality disorders on treatment outcome of anxiety disorders: best-evidence synthesis.

Authors:  L Dreessen; A Arntz
Journal:  Behav Res Ther       Date:  1998-05

10.  Health inequalities among British civil servants: the Whitehall II study.

Authors:  M G Marmot; G D Smith; S Stansfeld; C Patel; F North; J Head; I White; E Brunner; A Feeney
Journal:  Lancet       Date:  1991-06-08       Impact factor: 79.321

View more
  9 in total

1.  Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.

Authors:  R C Kessler; N A Sampson; P Berglund; M J Gruber; A Al-Hamzawi; L Andrade; B Bunting; K Demyttenaere; S Florescu; G de Girolamo; O Gureje; Y He; C Hu; Y Huang; E Karam; V Kovess-Masfety; S Lee; D Levinson; M E Medina Mora; J Moskalewicz; Y Nakamura; F Navarro-Mateu; M A Oakley Browne; M Piazza; J Posada-Villa; T Slade; M Ten Have; Y Torres; G Vilagut; M Xavier; Z Zarkov; V Shahly; M A Wilcox
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-27       Impact factor: 6.892

2.  Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study.

Authors:  Jerome H Taylor; Eli R Lebowitz; Ewgeni Jakubovski; Catherine G Coughlin; Wendy K Silverman; Michael H Bloch
Journal:  J Clin Child Adolesc Psychol       Date:  2017-09-28

3.  Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Authors:  Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch
Journal:  Neuropsychopharmacology       Date:  2017-08-29       Impact factor: 7.853

4.  Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial.

Authors:  Jerome H Taylor; Ewgeni Jakubovski; Michael H Bloch
Journal:  J Psychiatr Res       Date:  2015-04-04       Impact factor: 4.791

5.  Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial.

Authors:  Ewgeni Jakubovski; Michael H Bloch
Journal:  Psychiatr Q       Date:  2016-09

6.  Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia.

Authors:  Benedikt Sundermann; Jens Bode; Ulrike Lueken; Dorte Westphal; Alexander L Gerlach; Benjamin Straube; Hans-Ulrich Wittchen; Andreas Ströhle; André Wittmann; Carsten Konrad; Tilo Kircher; Volker Arolt; Bettina Pfleiderer
Journal:  Front Psychiatry       Date:  2017-06-09       Impact factor: 4.157

7.  Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.

Authors:  Shabah Mohammad Shadli; Tame Kawe; Daniel Martin; Neil McNaughton; Shona Neehoff; Paul Glue
Journal:  Int J Neuropsychopharmacol       Date:  2018-08-01       Impact factor: 5.176

Review 8.  Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review.

Authors:  Khatiya Moon; Michael Sobolev; John M Kane
Journal:  JMIR Ment Health       Date:  2022-02-16

9.  Neural Circuits Underlying Social Fear in Rodents: An Integrative Computational Model.

Authors:  Valerio Alfieri; Andrea Mattera; Gianluca Baldassarre
Journal:  Front Syst Neurosci       Date:  2022-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.